NDAPERIODONTALGEL
Approved
Dec 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORAQIX is a topical gel formulation containing lidocaine and prilocaine, two local anesthetics administered via the periodontal route. It is indicated for anesthesia during periodontal procedures such as scaling and root planing. The combination provides rapid onset and effective local numbing without systemic absorption.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), signaling potential team downsizing or transition focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ORAQIX represents a late-stage product career assignment with minimal expansion opportunity. Limited linked job openings (0) reflect the product's maturity and approaching loss of exclusivity, making this a consolidation rather than growth opportunity.
Brand ManagerField Sales Representative
Worked on ORAQIX at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.